Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) announced on October 27, 2026, that it will discontinue development of its AlloNK (AB-101) cell therapy following a review of updated clinical results, longer-term patient outcomes and two fatal safety events involving participants in its clinical studies.
The San Diego-based biotechnology company also announced plans to reduce its workforce by approximately 94% and evaluate strategic alternatives, including a potential merger, business combination, asset sale, licensing transaction or liquidation.
Artiva reported preliminary cash, cash equivalents and investments of approximately $319.1 million as of September 30, 2026.
Why Has Artiva Biotherapeutics Discontinued AlloNK Development?
Artiva decided to end development of AlloNK following an assessment of the treatment’s overall risk-benefit profile, updated clinical data and the potential commercial outlook.
AlloNK is a non-genetically modified, allogeneic natural killer (NK) cell therapy that was being evaluated in combination with rituximab for rheumatoid arthritis and other autoimmune diseases driven by B cells.
The company said updated clinical findings continued to demonstrate B-cell depletion and clinical activity consistent with previously reported results.
However, longer-term follow-up showed that the durability of clinical responses did not meet the level Artiva considered necessary to justify continued development.
The company also considered recent safety events, potential delays to clinical trial enrollment and the broader development outlook before deciding to discontinue the program.
What Safety Events Were Reported During the Clinical Trials?
Artiva disclosed two Grade 5 safety events involving participants in its clinical studies. Grade 5 is the classification used for a fatal adverse event.
The first involved a participant in the company’s Phase 2a basket trial who experienced fatal leukoencephalopathy, a neurological condition affecting the brain’s white matter, following study treatment.
The treatment regimen included lymphodepletion with cyclophosphamide and fludarabine, as specified in the study protocol.
The investigator and an independent safety review assessed the fatal neurological event as likely related to fludarabine-associated neurotoxicity.
Artiva reported the event to the U.S. Food and Drug Administration (FDA), clinical investigators and the Data Safety Monitoring Board.
Following notification, the FDA requested that the company pause enrollment and dosing in the Phase 2a trial.
Artiva also paused its planned Phase 3 study.
What Is Known About the Second Patient Death?
The second participant died suddenly approximately two months after beginning study treatment.
According to Artiva, the investigator assessed the death as unrelated to AlloNK or any other component of the treatment regimen.
The cause of death has not been determined.
Artiva reported the event to the FDA, investigators and the Data Safety Monitoring Board.
The company did not identify a confirmed treatment-related cause for the second death in its announcement.
What Did Artiva’s Chief Executive Say About the Decision?
Fred Aslan, M.D., Chief Executive Officer of Artiva Biotherapeutics, commented on the decision to discontinue development and pursue strategic alternatives.
“After careful consideration, we have made the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives,” Aslan said.
“Throughout the development of AlloNK, the safety and well-being of patients have remained our highest priority. We are deeply saddened by the deaths of two patients who participated in our clinical studies and extend our sincere condolences to their families. We plan to provide findings from the first case, which was assessed as likely related to fludarabine toxicity, given its widespread use in cell therapy conditioning regimens.”
Aslan also acknowledged the contributions of employees, patients and clinical investigators.
“I am incredibly proud of the Artiva team and grateful for their dedication, professionalism and deep commitment to patients. We also thank the patients, families and investigators who have contributed to advancing our understanding of AlloNK and its potential role in the treatment of autoimmune diseases,” Dr. Aslan added.
What Happens to the Ongoing AlloNK Clinical Trials?
Artiva confirmed that no additional patients will receive AlloNK in any ongoing clinical study.
The company will also abandon plans to initiate its Phase 3 pivotal trial.
Artiva intends to work with the FDA, clinical investigators and institutional review boards to complete an orderly closure of the clinical development program.
The process will include continued patient safety monitoring and regulatory reporting where required.
Although further dosing will stop, the company will maintain the follow-up activities necessary to address patient safety and regulatory obligations.
Will Artiva Publish Details of the Fludarabine-Associated Safety Event?
Artiva plans to share additional information about the fatal neurological event assessed as likely related to fludarabine toxicity.
The company intends to publish the findings in a scientific publication.
Fludarabine is used in lymphodepletion regimens that prepare patients for certain cell therapies.
Artiva cited the wider use of fludarabine-containing regimens in cell therapy development as a reason for making the case findings available to the scientific community.
The company did not provide a publication date.
What Happens to the Planned ACR Convergence 2026 Presentation?
Artiva will no longer present its previously announced clinical data at ACR Convergence 2026.
The company has also cancelled its investor webcast scheduled for November 9, 2026.
The decisions follow the termination of the AlloNK clinical development program.
Artiva indicated that updated clinical data could be presented at future scientific meetings, depending on the outcome of its strategic alternatives review.
No alternative presentation date has been announced.
Why Is Artiva Reducing Its Workforce by Approximately 94%?
Artiva announced a workforce reduction of approximately 94% as part of its corporate restructuring.
The measure follows the decision to discontinue AlloNK development and is intended to preserve capital while the company evaluates its strategic options.
The announcement did not specify the number of employees affected or provide a timetable for completing the workforce reduction.
The restructuring represents a substantial reduction in Artiva’s operating activities as it moves away from further clinical development of its lead therapy candidate.
What Strategic Alternatives Is Artiva Considering?
Artiva’s Board of Directors has initiated a review of internal options and potential strategic transactions intended to maximize stockholder value.
The company identified several possible outcomes, including a merger, business combination, sale or licensing of assets, dissolution and liquidation.
Artiva has engaged Leerink Partners as its financial advisor to assist with the review.
The company emphasized that there is no assurance the process will result in a transaction or any particular outcome.
No definitive agreement or transaction has been announced.
How Much Cash Does Artiva Have?
Artiva reported preliminary cash, cash equivalents and investments of approximately $319.1 million as of September 30, 2026.
The figure is unaudited and remains subject to adjustment.
The company expects to provide complete quarterly financial results in its Form 10-Q filing for the period ended September 30, 2026.
Artiva cautioned that its final reported cash, cash equivalents and investments may differ from the preliminary amount.
The company’s available financial resources will be relevant to its restructuring activities and strategic review, although no revised cash expenditure forecast was provided.
Will Artiva Provide Further Updates on the Strategic Review?
Artiva said it does not intend to provide regular updates on the strategic alternatives process.
Further announcements are expected only if the Board of Directors approves a specific course of action, the review concludes, or additional disclosure becomes appropriate or legally required.
The company has not provided a timetable for completing the process.
What Does the Announcement Mean for Artiva’s Future Operations?
The decision ends further clinical development of AlloNK, which had been Artiva’s lead therapeutic candidate.
The company will now focus on completing the clinical program’s closure, meeting continuing patient safety obligations, implementing its workforce reduction and evaluating potential corporate transactions.
Its strategic options include transactions that could result in a continuation of corporate operations under a different structure, as well as dissolution and liquidation.
The outcome remains uncertain, and Artiva has not committed to any particular alternative.
The company’s next disclosures are expected to provide additional information about its financial position, the restructuring and any decision reached through the strategic review.
More About Artiva Biotherapeutics
Artiva Biotherapeutics is a clinical-stage biotechnology company headquartered in San Diego, California.
The company has focused on developing allogeneic natural killer cell therapies for autoimmune diseases.
Its lead candidate, AlloNK (AB-101), was a non-genetically modified, cryopreserved NK cell therapy evaluated in combination with B-cell-targeted monoclonal antibodies.
On October 27, 2026, Artiva announced that it would discontinue AlloNK development and begin evaluating strategic alternatives.